Maridebart Cafraglutide
MariTide · AMG 133
A conjugate pairing a GIP receptor antagonist antibody with GLP-1 receptor agonist peptides, studied in trials for weight management on a monthly schedule. Its design is the mirror image of the dual agonist approach, blocking the GIP receptor rather than activating it. Not approved.
Tracking and educational reference only, on values you enter yourself. Not medical advice or a dosing recommendation.
Half-life
Long enough to support the once-monthly schedule used in trials. Half-life is an educational pharmacology figure, drawn from public sources, and is not a schedule or dosing instruction.
Storage & handling
Investigational; no approved label defines handling.
References
- NEJM 2025: once-monthly maridebart cafraglutide for the treatment of obesity, a phase 2 trial
Read the source
Related in GLP-1 / Metabolic
Educational reference only, compiled from public sources. Not medical advice, diagnosis, treatment, or a dosing recommendation, and not a recommendation to use any compound. Many compounds listed are research materials not approved for human use. Consult a qualified professional.